I have just finished attending the sixth World Congress on Positive Psychology in Melbourne and technology was a big talking point.
In some circles it was discussed as a major factor and contributor to increased stress, depression and anxiety.
But I was also pleased to see that there were a number of sessions on the positive impacts technology can have, in the right hands.
Used for good rather than evil, if you like.
During the four day congress, I had the pleasure of chatting with Stephen Schueller, Assistant Professor at UCLA, and Lyle Ungar, Professor of Operations, Information and Decisions at the Wharton School at the University of Pennsylvania. Both have much longer credentials than you or I want to read but, sufficed to say, these guys are super smart.
Both men gave sessions on uses of technology in psychology, specifically around ways to intervene and improve the wellbeing of people.
Two apps that were mentioned, and I think are worth looking at, are Happify and Jo: the smart journal. The former, was developed by some of the world's leading positive psychology practitioners, with a user interface created by game developers. Happify is an evidence-based app for better mental health and wellbeing, especially for people suffering from depression.
The second app, Jo: the smart journal, utilises an algorithm, to help not only encourage users to do a daily journal on what makes them feel good, but over time, build on its understanding of what they like, want to improve on, and reminds and even suggests, ways to achieve this.
I am hoping to catch up with Phillip Daffas, CEO of Painchek (ASX:PCK) soon.
I am keen to find out how the clinical test of the PainChek® App for infants is going in Melbourne, and when we might get the results.
PainChek® App for infant is being trialled in the Emergency Department of the Royal Children’s Hospital.
In the study, pain scores derived using the PainChek® Infant App will be compared to those obtained using observational children’s pain assessment tools by two independent assessors, to gauge how the Painchek tech stacks up.
I have interviewed Phil Daffas a number of times, and it might be worth having a look if you haven't seen them already.
Another trial I am keeping a weather eye on, is the latest being conducted by ResApp Health Limited (ASX:RAP).
The company is developing smartphone applications for the diagnosis and management of multiple respiratory diseases. It currently has 200 patients in a double-blind, at home obstructive sleep apnoea (OSA) study.
The company has already confirmed that ResApp’s algorithms accurately identify obstructive sleep apnoea, from a patient’s overnight breathing and snoring sounds. This was done using a smartphone placed on a bedside table, to record people during a sleep laboratory study.
This latest trial has people using the app at home, not in the lab, and is tipped to show results sometime in the third calendar quarter.
The fashion business is very bullish on sustainable materials and Nanollose has, what it describes as, "the ability to create ecofriendly tree-free nonwoven fabric."
The latest announcement was at a pilot scale size, but significantly, according to Nanollose, used standard industrial equipment and processes currently used by manufacturers.
This will make a deal with a major fashion company, like a Zara or H&M, much easier to get across the line. No reinventing the wheel stuff needed.
The company's CEO, Alfie Germano, is also well connected in the fashion biz, so it will be interesting to see how it plays out. I have also interviewed Alfie a couple of times, and these could be worth a listen, if you have time.
Have a great week ahead!
We do not recommend or advise to buy or sell shares in any of the companies mentioned in this article. The InsideMarket Private Fund does may own shares in some of the companies mentioned in this article. However, we have not received any payment from any company for coverage in this article or anywhere else on the InsideMarket.net site. Disruptive technology stocks should be considered very speculative, high-risk, and very volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.